We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CureVac’s COVID-19 Vaccine Only 48 Percent Effective in Phase 3 Study
CureVac’s COVID-19 Vaccine Only 48 Percent Effective in Phase 3 Study
CureVac’s messenger-RNA (mRNA)-based COVID-19 vaccine, CVnCoV, was just 48 percent effective in a final analysis from a late-stage trial ― one percentage point higher than reported in an earlier phase 3 analysis and still below the FDA’s 50 percent efficacy threshold required for Emergency Use Authorization.